Aristotle Capital Boston LLC lessened its position in shares of Chemed Co. (NYSE:CHE) by 8.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,692 shares of the company’s stock after selling 4,928 shares during the period. Chemed comprises 1.3% of Aristotle Capital Boston LLC’s holdings, making the stock its 22nd largest position. Aristotle Capital Boston LLC’s holdings in Chemed were worth $17,159,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Laurion Capital Management LP bought a new position in Chemed during the 2nd quarter worth about $492,000. Marshall Wace LLP bought a new position in Chemed during the 2nd quarter worth about $1,433,000. First Trust Advisors LP increased its holdings in Chemed by 370.3% during the 3rd quarter. First Trust Advisors LP now owns 81,596 shares of the company’s stock worth $26,076,000 after purchasing an additional 64,248 shares in the last quarter. Virginia Retirement Systems ET AL increased its holdings in Chemed by 18.1% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 91,400 shares of the company’s stock worth $29,210,000 after purchasing an additional 14,000 shares in the last quarter. Finally, US Bancorp DE increased its holdings in Chemed by 2.3% during the 3rd quarter. US Bancorp DE now owns 16,755 shares of the company’s stock worth $5,355,000 after purchasing an additional 376 shares in the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

In related news, insider Spencer S. Lee sold 669 shares of the firm’s stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $314.76, for a total value of $210,574.44. Following the completion of the sale, the insider now directly owns 30,589 shares in the company, valued at approximately $9,628,193.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Naomi C. Dallob sold 5,500 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $317.23, for a total transaction of $1,744,765.00. Following the completion of the sale, the vice president now owns 11,122 shares of the company’s stock, valued at $3,528,232.06. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,953 shares of company stock valued at $7,678,463. Company insiders own 4.90% of the company’s stock.

A number of equities analysts have recently commented on CHE shares. Zacks Investment Research downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research note on Tuesday, September 25th. Bank of America started coverage on shares of Chemed in a research note on Friday, October 12th. They set a “buy” rating and a $390.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $332.00.

Chemed stock opened at $305.99 on Friday. Chemed Co. has a one year low of $234.00 and a one year high of $335.99. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.14 and a quick ratio of 1.11. The stock has a market cap of $4.85 billion, a PE ratio of 57.09, a price-to-earnings-growth ratio of 2.66 and a beta of 1.18.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Monday, October 29th. The company reported $3.07 EPS for the quarter, topping the Zacks’ consensus estimate of $2.80 by $0.27. Chemed had a net margin of 11.73% and a return on equity of 35.13%. The company had revenue of $444.15 million during the quarter, compared to the consensus estimate of $445.16 million. During the same period in the prior year, the business posted $2.15 EPS. The company’s quarterly revenue was up 6.4% on a year-over-year basis. On average, sell-side analysts expect that Chemed Co. will post 11.41 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 3rd. Stockholders of record on Monday, November 12th were paid a dividend of $0.30 per share. The ex-dividend date was Thursday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.39%. Chemed’s dividend payout ratio is 22.39%.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/chemed-co-che-position-lowered-by-aristotle-capital-boston-llc/2666516.html.

Chemed Profile

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Read More: What is a capital gain?

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.